ZVRAZevra Therapeutics, Inc.
$11.00+7.9% 1Y
$11.00
$8.1052 weeks$14.74
The financials
Zevra Therapeutics, Inc. by the numbers
Zevra Therapeutics, Inc. (ZVRA) reported revenue of $40M in Q2 2026 (quarter ended Jun 30, 2026), up 53% from the same quarter a year earlier. That came with a gross margin of 96% and net income of $8.8M (22% of revenue). For the full year FY2025, revenue was $106M (+351% year on year) and net income $83M. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $40M | $26M | +53% |
| Gross profit | $38M | $14M | +182% |
| Operating income | $17M | −$71M | to a profit |
| Net income | $8.8M | $75M | −88% |
| Diluted EPS | $0.14 | $1.21 | −88% |